Favorable End-of-Phase 2 meeting with U.S. FDA for [18F]FAPI-74 for GI cancers Primary and secondary endpoints met Alignment with FDA…
MESA, ARIZONA / ACCESS Newswire / October 1, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE), an emerging developer of…
Secure, scalable, multi-cloud platform using federated learning aims to accelerate cancer discoveries and treatments SEATTLE, WASHINGTON / ACCESS Newswire /…
Study to accelerate access to brain-computer interface technology, using Apple Vision Pro, for people with ALS, spinal cord injury (SCI),…
Study to accelerate access to brain-computer interface technology, using Apple Vision Pro, for people with ALS, spinal cord injury (SCI),…
Prioritizes High-Value Approved Drugs in Multi-Billion-Dollar Markets to Accelerate CommercializationFuture Platform Expansion into CNS, Men's Health, and Anti-Nausea ESTERO, FL…
The approach defies the restrictive weight loss paradigm, with early results indicating increased meal tracking and member engagement1 with new…
Los Angeles, CA, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a…
Pr. Yann Gouëffic and affiliates (FRANCE-PAD) cover ~8% of all CLTI cases in France BERKELEY, Calif, Oct. 01, 2025 (GLOBE…
CAMBRIDGE, Mass., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Ernexa Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of…